康寧傑瑞製藥-B(09966.HK)授出合共12萬股獎勵股份
格隆匯5月29日丨康寧傑瑞製藥-B(09966.HK)公告,2025年5月29日,根據限制性股份獎勵計劃,公司決議向三名合資格參與者授出合共120,000股獎勵股份,該等獎勵董事包括一名公司非執行董事及兩名獨立非執行董事。
授出獎勵股份旨在:(i)肯定獎勵董事對集團所作的貢獻;(ii)獎勵對集團持續經營、發展及長期增長作出有利貢獻的獎勵董事;及(iii)將股東、公司及獎勵董事的利益緊密結合並使彼等共擔風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.